Related Experiment Videos
[Austrian complex-study on dipropylacetate. Pediatric experiences]
Padiatrie Und Padologie
|January 1, 1976
Summary
Dipropylacetat (Convulex) is effective for primary generalized epilepsies, including Lennox-Syndrome, with fewer side effects than standard anticonvulsants. It offers good therapeutic effects, especially in newly diagnosed patients, with a recommended dosage of 20-50 mg/kg/day for children.
Area of Science:
- Neurology
- Clinical Pharmacology
Context:
- Multicenter clinical trials are crucial for gathering reliable data efficiently.
- Dipropylacetat (DPA) is an anticonvulsant medication used in epilepsy treatment.
Purpose:
- To evaluate the efficacy, safety, and optimal dosage of Dipropylacetat (Convulex) in a multicenter clinical trial.
- To compare Convulex with standard anticonvulsants in treating various epilepsy types, particularly in treatment-naive patients.
Summary:
- The study demonstrated Dipropylacetat's (Convulex) good therapeutic effect in primary generalized epilepsies, irrespective of seizure type, and showed promising results in Lennox-Syndrome.
- Convulex exhibited comparable efficacy to standard anticonvulsants but with significantly reduced side effects, notably less sedation, especially in previously untreated patients.
- Therapeutic effects were observed earlier in treatment-naive individuals compared to those on prior medication. A recommended dosage of 20-50 mg/kg/day for children was established, with potential increases up to 120 mg/kg/day in some cases.
Impact:
- Provides evidence for Dipropylacetat (Convulex) as an effective and well-tolerated alternative for epilepsy management, particularly in specific syndromes and newly diagnosed cases.
- Highlights the benefits of well-organized multicenter studies in rapidly obtaining reliable clinical information on antiepileptic drugs.
- Suggests a favorable side-effect profile, especially reduced sedation, making Convulex a potentially valuable option for pediatric epilepsy treatment.